AI in Prostate Cancer Screening & Diagnosis: A Registry-Based Study of ClinicalTrials.gov Trials.

Introduction: Artificial intelligence (AI) is increasingly applied in prostate cancer screening and diagnostic evaluation; however, the structure, methodological characteristics, and clinical positioning of AI-focused trials remain incompletely characterized. This study aimed to map the clinical tri...

Descripción completa

Detalles Bibliográficos
Publicado en:Inquiry (00469580) Vol. 63; pp. 1 - 15
Autores principales: Hareeri, Rawan H., Aldurdunji, Mohammed M.
Formato: research tables/charts Journal Article
Publicado: Sage Publications Inc. 6/16/2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=194639611&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 194639611
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00469580
        INQ
      jtl: Inquiry (00469580)
      issn: 00469580
      maglogo: Y
    pubinfo:
      dt: 6/16/2026
      vid: 63
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        194639611
        194639611
        194639611
        10.1177/00469580261457387
        194639611
      ppf: 1
      ppct: 14
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: AI in Prostate Cancer Screening & Diagnosis: A Registry-Based Study of ClinicalTrials.gov Trials.
      aug:
        au:
          Hareeri, Rawan H.
          Aldurdunji, Mohammed M.
        affil: Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
      sug:
        subj:
          Prostatic Neoplasms Diagnosis
          Cancer Screening Methods
          Artificial Intelligence Utilization
          Clinical Trials
          Medical Practice, Evidence-Based
          Human
          Male
          Magnetic Resonance Imaging
          Positron-Emission Tomography
          Prostate Ultrasonography
          Tomography, X-Ray Computed
          Descriptive Statistics
          Funding Source
          Male
      ab: Introduction: Artificial intelligence (AI) is increasingly applied in prostate cancer screening and diagnostic evaluation; however, the structure, methodological characteristics, and clinical positioning of AI-focused trials remain incompletely characterized. This study aimed to map the clinical trial landscape of AI applications in prostate cancer diagnosis using registry-based evidence mapping. Methods: A registry-based evidence-mapping analysis was conducted using ClinicalTrials.gov. Trials registered up to 15 November 2025 were systematically identified using search terms related to prostate cancer and AI-based methodologies. Eligible studies included interventional and observational trials evaluating AI applications for diagnostic purposes. Data were extracted on study design, diagnostic modality, functional role of AI, comparator framework, and validation strategy. Descriptive statistics and cross-tabulation analyses were used to characterize patterns across studies. The study selection process was presented using a PRISMA-style flow diagram. Results: A total of 84 trials met the inclusion criteria. Imaging-based AI applications predominated, accounting for 52.4% of studies, with magnetic resonance imaging (MRI) representing the most frequently investigated modality (34.5%). Biomarker-based (16.7%), multimodal (15.5%), and computational pathology (7.1%) approaches were less frequently reported. The most common functional applications were classification and risk prediction (48.8%) and lesion detection and segmentation (29.8%). Most studies employed prospective observational designs (84.5%) and frequently relied on stand-alone AI evaluation frameworks (39.2%). Histopathology or biopsy confirmation was the most commonly reported reference standard (56.0%). Only a limited number of trials incorporated workflow integration or clinical decision-support evaluation. Conclusion: AI research in prostate cancer diagnostics appears to be primarily centered on imaging-based, early-phase, and performance-oriented studies. Current evidence suggests that AI systems are predominantly positioned as decision-support tools rather than fully integrated clinical solutions. Greater emphasis on multicenter validation, standardized reporting, and clinically relevant outcome evaluation may be required to support broader clinical implementation.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N